Citadel Advisors’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-8,300
| Closed | -$214K | – | 13826 |
|
|
2025
Q3 | $214K | Sell |
8,300
-6,132
| -42% | -$80.2K | ﹤0.01% | 11130 |
|
|
2025
Q2 | $115K | Buy |
14,432
+14,419
| +110,915% | +$110K | ﹤0.01% | 11212 |
|
|
2025
Q1 | $122 | Sell |
13
-6,875
| -100% | -$67.6K | ﹤0.01% | 14327 |
|
|
2024
Q4 | $87.1K | Buy |
6,888
+6,588
| +2,196% | +$83.7K | ﹤0.01% | 11672 |
|
|
2024
Q3 | $4.82K | Sell |
300
-5,563
| -95% | -$113K | ﹤0.01% | 13540 |
|
|
2024
Q2 | $143K | Sell |
5,863
-3,600
| -38% | -$166K | ﹤0.01% | 10410 |
|
|
2024
Q1 | $680K | Buy |
9,463
+8,238
| +672% | +$1.15M | ﹤0.01% | 7727 |
|
|
2023
Q4 | $244K | Buy |
1,225
+25
| +2% | +$3.1K | ﹤0.01% | 9574 |
|
|
2023
Q3 | $160K | Buy |
1,200
+525
| +78% | +$85.7K | ﹤0.01% | 10256 |
|
|
2023
Q2 | $101K | Sell |
675
-438
| -39% | -$68.2K | ﹤0.01% | 10923 |
|
|
2023
Q1 | $163K | Buy |
1,113
+1,013
| +1,013% | +$205K | ﹤0.01% | 10494 |
|
|
2022
Q4 | $15.8K | Buy |
+100
| New | +$16K | ﹤0.01% | 13305 |
|
|
2021
Q3 | – | Sell |
-20,363
| Closed | -$5.18M | – | 14493 |
|
|
2021
Q2 | $5.18M | Buy |
20,363
+10,263
| +102% | +$1.92M | ﹤0.01% | 4348 |
|
|
2021
Q1 | $1.79M | Sell |
10,100
-975
| -9% | -$161K | ﹤0.01% | 6657 |
|
|
2020
Q4 | $1.75M | Buy |
+11,075
| New | +$2.41M | ﹤0.01% | 5634 |
|
Citadel Advisors's RAPT Position: Q1 2026 in Review
Citadel Advisors sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 591,802 shares — an estimated $20M sold.
Citadel Advisors first reported a position in RAPT in Q3 2021 and held it in 14 quarters. The position peaked at $20M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Citadel Advisors reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 591,802 RAPT Therapeutics shares in Q1 2026, an estimated $20M.
- Citadel Advisors first reported a position in RAPT Therapeutics in Q3 2021 and held it in 14 quarters.
- Citadel Advisors's RAPT Therapeutics position peaked at $20M in Q4 2025.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.